Intercell had an active 2012 first quarter, increasing sales of its vaccine against Japanese encephalitis, while starting clinical studies in candidate vaccines for tuberculosis, Pseudomonas aeruginosa and Clostridium difficile. ---Subscribe to MedNous to access this article--- Company News
